| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/21/2007 | US20070141323 Compositions and aqueous dispersions |
| 06/21/2007 | US20070141221 Edible oils consisting of medium chain triglyceride oils interesterified with long chain domestic oils and phytosterols; cholesterol lowering and metabolic benefits |
| 06/21/2007 | US20070141211 Encapsulated Phospholipid-Stabilized Oxidizable Material |
| 06/21/2007 | US20070141185 Oral microemulsion composition comprising biphenydimethyldicarboxylate and silybin |
| 06/21/2007 | US20070141184 Composition for oral administration containing capsaicinoids |
| 06/21/2007 | US20070141173 Medicament comprising noble metal fine particles |
| 06/21/2007 | US20070141165 Method for Manufacturing Microcapsules Containing Capsinoid |
| 06/21/2007 | US20070141164 Methods and gel compositions for encapsulating living cells and organic molecules |
| 06/21/2007 | US20070141163 Smart bio-nanoparticle elements |
| 06/21/2007 | US20070141162 Injectable compositions for the controlled delivery of pharmacologically active compound |
| 06/21/2007 | US20070141161 Liquid ganaxolone formulations and methods for the making and use thereof |
| 06/21/2007 | US20070141160 Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
| 06/21/2007 | US20070141159 Contacting a poorly soluble drug with a vinyl acetate-vinyl pyrrolidone copolymer to absorb the polymer to the surface of the drug |
| 06/21/2007 | US20070141158 Amphiphilic heparin derivative formed by coupling a heparin with a bile acid |
| 06/21/2007 | US20070141157 Method for producing antibiotic/antibiotics and their use |
| 06/21/2007 | US20070141156 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis |
| 06/21/2007 | US20070141155 Immediate-release; allows a single drug or a mixture of two drugs to be accurately divided in halves with regard to the dose, even if the tablet does not break into equal halves by mass; warfarin, a statin, risperidone, methotrexate, metformin, atenolol, prednisone, phenytoin, lamotrigine, meloxicam |
| 06/21/2007 | US20070141154 Antidiabetic formulation and method |
| 06/21/2007 | US20070141153 Orally administered pharmaceutical composition |
| 06/21/2007 | US20070141152 Orally administered pharmaceutical composition |
| 06/21/2007 | US20070141151 Lansoprazole orally disintegrating tablets |
| 06/21/2007 | US20070141150 Pharmaceutical composition |
| 06/21/2007 | US20070141149 Controlled-release pharmaceutical formulation |
| 06/21/2007 | US20070141148 Neramexane MR matrix tablet |
| 06/21/2007 | US20070141147 Sequential release pharmaceutical formulations |
| 06/21/2007 | US20070141146 Novel compositions |
| 06/21/2007 | US20070141145 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
| 06/21/2007 | US20070141144 Oral delivery system |
| 06/21/2007 | US20070141143 Solid compositions of low-solubility drugs and poloxamers |
| 06/21/2007 | US20070141142 Pseudo-thermosetting neutralized chitosan composition forming a hydrogel and a process for producing the same |
| 06/21/2007 | US20070141141 Pharmaceutical composition |
| 06/21/2007 | US20070141140 Semi-solid formulations for immediate release intended for the oral administration of drugs |
| 06/21/2007 | US20070141138 Omega 3 fatty acid formulations |
| 06/21/2007 | US20070141137 Stable capsule preparation |
| 06/21/2007 | US20070141136 intravenously administering to mammal a therapeutically effective amount of a liposomal suspension of small unilamellar vesicles (SUVs), wherein SUVs predominantly comprise phospholipids selected from phosphatidycholine, phosphatidylglycerol and phosphatidylserine |
| 06/21/2007 | US20070141135 Compositions and methods for less immunogenic protein-lipid complexes |
| 06/21/2007 | US20070141134 Shielded micelles for polynucleotide delivery |
| 06/21/2007 | US20070141133 Liposomes; analgesics; glutathione is covalently bound to polyethylene glycol,wherein the polyethylene glycol is covalently bound to vitamin E or a phospholipid |
| 06/21/2007 | US20070141132 Human growth hormone patch formulations |
| 06/21/2007 | US20070141127 Wet wipes with natural antimicrobial agents |
| 06/21/2007 | US20070141126 Germicidal surface-covering assembly |
| 06/21/2007 | US20070141125 Thermal image with antimicrobial property |
| 06/21/2007 | US20070141117 Melt extrusion of a mixture of memantine and biodegradable glycolic acid-lactic acid copolymer to make a sustained release implant to last for one week; glaucoma and proliferative vitreoretinopathy |
| 06/21/2007 | US20070141115 Drug delivery systems |
| 06/21/2007 | US20070141105 Engineered Biological Matrices |
| 06/21/2007 | US20070141102 Drug delivery system based on polyethylene vinylacetate copolymers |
| 06/21/2007 | US20070141096 Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| 06/21/2007 | US20070141093 an oil-in-water emulsion, a water-in-oil emulsion or micelle formulation selected from sebacate bis(paclitaxel-2'-yl) ester and sebacate bis(docetaxel-2'-yl) ester, used for for treating lung, mammary gland, colon or ovarian cancer |
| 06/21/2007 | US20070141092 Biguanide composition and method of treatment and prevention of viral infections |
| 06/21/2007 | US20070141091 Biguanide ointment and method of treatment and prevention of infections |
| 06/21/2007 | US20070141090 Microemulsion preparation of high concentration propofol for anesthetic uses |
| 06/21/2007 | US20070141089 Topical composition comprising terbinaf ine adn hydrocortisone |
| 06/21/2007 | US20070141078 Monovalent; low dose of egg-derived influenza virus antigen from an influenza virus strain associated with or having the potential to cause a pandemic outbreak (e.g. H5N1antigen), with an oil in water emulsion adjuvant of an oil, alpha-tocopherol, and an emulsifier; can be made quickly in pandemic |
| 06/21/2007 | US20070141039 Bifidobacterium longum infantis strain secretes a factor that antagonizes the activity ofpro-inflammatory cytokine selected from TNF- alpha, IL-8, IFN gamma to treat inflammatory bowel disease or irritable bowel syndrome |
| 06/21/2007 | US20070141022 Polymeric delivery agents and delivery agent compounds |
| 06/21/2007 | US20070140988 Therapeutic agent for periodontal disease |
| 06/21/2007 | US20070140987 Promoting whole body health |
| 06/21/2007 | US20070140984 Functional powdery product |
| 06/21/2007 | US20070140983 Ion Exchange Resin Treated to Control Swelling |
| 06/21/2007 | US20070140982 Diuretic Aerosols and Methods of Making and Using Them |
| 06/21/2007 | US20070140981 Intranasal compositions |
| 06/21/2007 | US20070140980 Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation |
| 06/21/2007 | US20070140979 Method for accelerating the rate of mucociliary clearance |
| 06/21/2007 | US20070140978 Adrenergic complement inhaler |
| 06/21/2007 | US20070140977 Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same |
| 06/21/2007 | US20070140976 Aqueous inhalation pharmaceutical composition |
| 06/21/2007 | US20070140975 Opioid formulations having reduced potential for abuse |
| 06/21/2007 | US20070140972 Targeting compositions and preparation therof |
| 06/21/2007 | DE102005060393A1 Pharmaceutical pellet, useful for the production of tablet, comprises a spherical active agent, preferably metroprololsuccinate, comprising core with smooth surface and a coat on the core, where the active agent release is pH-independent |
| 06/21/2007 | DE102005059602A1 Verfahren zur Mikronisierung Process for the micronization |
| 06/21/2007 | DE10016356B4 Mittel mit verbesserter Retardwirkung und Verfahren zu dessen Herstellung Agents having improved sustained release and process for its preparation |
| 06/21/2007 | CA2634073A1 Compositions comprising ingenol-3-angelate |
| 06/21/2007 | CA2634006A1 Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine |
| 06/21/2007 | CA2633909A1 Modified and pulsatile release pharmaceutical formulations of escitalopram |
| 06/21/2007 | CA2633603A1 Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
| 06/21/2007 | CA2633489A1 Compositions and methods for treating dermatological conditions |
| 06/21/2007 | CA2633472A1 Flux-enabling compositions and methods for dermal delivery of drugs |
| 06/21/2007 | CA2633466A1 Spray-on formulations and methods for dermal delivery of drugs |
| 06/21/2007 | CA2633125A1 Adhesive pharmaceutical preparation containing bisoprolol |
| 06/21/2007 | CA2632831A1 Powder formulations for use in dry powder inhalers |
| 06/21/2007 | CA2631498A1 Hcv prodrug formulation |
| 06/21/2007 | CA2631497A1 Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase |
| 06/21/2007 | CA2631494A1 Processes for making particle-based pharmaceutical formulations for parenteral administration |
| 06/21/2007 | CA2631493A1 Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| 06/21/2007 | CA2631492A1 Processes for making particle-based pharmaceutical formulations for oral administration |
| 06/21/2007 | CA2631391A1 Aqueous-alcoholic depigmenting gel |
| 06/21/2007 | CA2629233A1 Cosmetic compositions with encapsulated pigments and a method for using |
| 06/21/2007 | CA2629046A1 Abuse resistant transmucosal drug delivery device |
| 06/21/2007 | CA2625640A1 Intravenous essential fatty acid emulsion |
| 06/20/2007 | EP1798504A1 Method of making dried particles |
| 06/20/2007 | EP1798285A1 Methods and medicament for inhibition the expression of a defined gene |
| 06/20/2007 | EP1797934A1 Process for producing finely particulate substance and finely particulate substance |
| 06/20/2007 | EP1797902A2 Particles for inhalation having sustained release properties |
| 06/20/2007 | EP1797884A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 06/20/2007 | EP1797874A1 Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation |
| 06/20/2007 | EP1797873A2 Compressed microparticles for dry injection |
| 06/20/2007 | EP1797872A1 Telmisartan-containing pharmaceutical compositions for oral intake |
| 06/20/2007 | EP1797871A1 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| 06/20/2007 | EP1797870A1 Oral delivery of protein drugs using microemulsion |
| 06/20/2007 | EP1797869A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |